Prescription Access resources. NeedyMeds. RxAssist.org. Together RX Access TogetherRxAccess.com

Save this PDF as:
 WORD  PNG  TXT  JPG

Size: px
Start display at page:

Download "Prescription Access resources. NeedyMeds. RxAssist.org. Together RX Access 800-444-4106. TogetherRxAccess.com"

Transcription

1 Prescription Access resources NeedyMeds RxAssist.org Together RX Access TogetherRxAccess.com The Partnership for Prescription Access 888-4PPA-NOW ( ) By Company: ABBOTT Abbott Patient Assistance Foundation (Lupron) Abbott Patient Assistance Foundation Abbott Patient Assistance Foundation - Diabetes Care Abbott Patient Assistance Foundation - Kaletra & Norvir Abbott Patient Assistance Foundation - Medical Nutrition Abbott Patient Assistance Foundation (HUMIRA) Abbott Patient Assistance Foundation (Zemplar)

2 ABRAXIS ONCOLOGY Abraxis Patient Access Program , opt 3 ACCREDO THERAPEUTICS Adagen Patient Assistance Program Flolan Patient Assistance Program ACORDA THERAPEUTICS Zanaflex Uninsured Individual Program ACTAVIS PHARMACEUTICALS Kadian Patient Assistance Program ACTELION PHARMACEUTICALS Tracleer Access Program opt. 1 Ventavis Patient Assistance Program ALAVEN PHARMACEUTICAL Alaven Patient Assistance Program ALCON LABS Alcon Cares ALEXION PHARMACEUTICALS

3 Alexion Complement Foundation ALKERMES, INC. Touchpoints AMERICAN REGENT Venofer Reimbursement Hotline and Patient Assistance Program AMGEN, INC. ENcourage Foundation Safety Net Foundation AMYLIN PHARMACEUTICALS, INC. Amylin Patient Assistance Program - Symlin ARCH FOUNDATION Arch Foundation Patient Assistance Program for Mirena ASCEND THERAPEUTICS Ascend Therapeutics Patient Assistance Program ASTELLAS PHARMA US, INC. Amevive Start Assistance Program Astellas Patient Assistance Program for Organ Transplant

4 Astellas Patient Assistance Program for Vaprisol Astellas Stock Replacement Program Protopic Patient Assistance Program ASTRAZENECA PHARMACEUTICALS AZ & Me Prescription Savings Program for people with Medicare Part D AZ & Me Prescription Savings Program for people without insurance AZ Cancert Support Network - Iressa Access Program ATON PHARMA Aton Pharma Patient Assistance Program AUXILIUM PHARMACEUTICALS, INC. Auxilium Patient Assistance Program AXCAN PHARMA, INC. Assist Program Care First for CF Program Comprehensive Care Program for CF

5 Rx Cost Reduction Program BAXTER HEALTHCARE CORPORATION Alpha-1 SecurityProgram CARES Gammagard Insurance Assistance program GARD (4273) WinRho Reimbursement Support and Patient Assistance Program , opt 3 BAYER HEALTHCARE PHARMACEUTICALS Bayer Patient Assistance Program - Angeliq Bayer Patient Assistance Program - Betapace Bayer Patient Assistance Program - Climara Bayer Patient Assistance Program - Climara Pro Bayer Patient Assistance Program - Menostar Bayer Patient Assistance Program for Precose Betaseron Patient Assistance Program

6 Kogenate Factor Solutions Nexavar REACH Program BEACH PHARMACEUTICALS BIOGEN Idec Access Program BIOMARIN KUVAN Patient Assistance Program Naglazyme Premium/Co-Payment Assistance Program BIOVITRUM Kepivance Patient Assistance Program Kineret Patient Assistance Program BLAIREX LABORATORIES Blairex Laboratories Indigent Program BOEHRINGER INGELHEIM CARES FOUNDATION, INC. Patient Assistance Program

7 Patient Assistance Program for Aptivus & Viramune Patient Assistance Program for Medicare Beneficiaries BRISTOL-MYERS SQUIBB Abilify Patient Assistance Program Access Virology Patient Assistance Program Atripla Patient Assistance Program Bristol-Myers Squibb Patient Assistance Foundation Inc Destination Access ERBITUX / IXEMPRA Patient Assistance Program Destination Access Sprycel Patient Assistance Program Oncology Patient Assistance Program Orencia Patient Assistance Program BTA PHARMACEUTICALS, INC. BTA Patient Assistance Program CELGENE CORPORATION Innohep Patient Assistance Program

8 Patient Support Coordinator CEPHALON, INC. Cephalon Oncology Reimbursement Expertise (CORE) CephalonCares Foundation Patient Assistance Program CETYLITE INDUSTRIES, INC. Cetylite Industries, Inc COLUMBIA LABORATORIES, INC. Medication Coupons option 2 CORNERSTONE BIOPHARMA Spectracef Voucher Program CSL BEHRING CSL Behring Patient Assistance Program CUBIST PHARMACEUTICALS Cubicin Reimbursement Hotline CV THERAPEUTICS CVT Connect Patient Assistance Program

9 DAIICHI SANKYO Daiichi Sankyo Open Care Program DIGESTIVE CARE, INC. Digestive Care, Inc. Assistance Program DIPLOMAT PHARMACY Crohn s Navigator Program ext DURAMED PHARMACEUTICALS, INC. Cenestin Patient Assistance Program Enjuvia Patient Assistance Program ParaGard Patient Assistance Program Seasonique Patient Assistance Program ECR PHARMACEUTICALS ECR Pharmaceuticals Patient Assistance Program EISAI, INC. Aricept Patient Assistance Program Eisai Assistance Program

10 Eisai Assistance Program - Oncology Eisai Neurology Patient Assistance Program Fragmin Reimbursement Assistance Gliadel Wafer Patient Assistance Program ELAN PHARMACEUTICALS Patient Assistance Program for Prialt Tysabri Patient Assistance Program ELI LILLY & COMPANY Forteo Patient Assistance Program Humatrope Reimbursement Center Lilly Cares LillyMedicareAnswers Program PatientOne Xigris Treatment Support Program

11 EMD SERONO Connections for Growth MS Lifelines Serostim Patient Assistance Program ENDO PHARMACEUTICALS, INC. Endo Patient Assistance Program Endo Patient Assistance Program for Opana Endo Patient Assistance Proram for Vantas ENZON Enzon Patient Assistance & Reimbursement Services EUSA PHARMA EUSA Pharma Community Access Patient Program EXPRESS SCRIPTS SPECIALTY DISTRIBUTION SERVICES Rx Outreach FERNDALE LABORATORIES, INC.

12 Ferndale Laboratories Patient Assistance Program , ext 442 FOREST PHARMACEUTICALS, INC Patient Assistance Program FRESENIUS MEDICAL CARE PhosLo Patient Assistance Program Venofer Patient Assistance Program GALDERMA LABORATORIES Patient Assistance Program GENENTECH, INC Access to Care Access to Care - Avastin, Herceptin, Rituxan, Tarceva Access to Care - Lucentis Access to Care - Nutropin (Adult) Access to Care - Nutropin (Pediatric) Access to Care - Pulmozyme

13 Access to Care - Rituxan RA Access to Care - Xolair Avastin Patient Assistance Program GENZYME CORPORATION Charitable Access Program ex Renal Patient Assistance Program , opt 2 Renvela Medicare Part D Assistance Program option 2 Synvisc Reimbursement Hotline GILEAD SCIENCES Gilead Advancing Access Letairis Education and Access Program (LEAP) GLAXOSMITHKLINE Bridges to Access Commitment to Access

14 GSK Access GLENWOOD & WESTERN MEDICAL Glenwood Compassionate Drug Program , ext. 1 GRACEWAY PHARMACEUTICALS Graceway Pharmaceuticals Patient Assistance Program GRIFOLS Grifols Assurance for Patients , option 3 Grifols Patient Assistance Program option 3 GTx, INC. GTx, Inc. Patient Assistance Program INTERMUNE PHARMACEUTICALS Actimmune Patient Assistance Program JAZZ PHARMACEUTICAL,INC. Xyrem Patient Assistance Program JOHNSON & JOHNSON HEALTH CARE SYSTEMS, INC. Janssen Ortho Patient Assistance Foundation KING PHARMACEUTICALS, INC.

15 KingKare Patient Assistance Program LUNDBECK, INC. Patient Assistance Program Xenazine Patient Assistance Program MALLINCKRODT Mallinckrodt Patient Assistance Program MEDA PHARMACEUTICALS Patient Assistance Program MEDIMMUNE, INC. Synagis Patient Assistance Program MEDTRONIC,INC. ITB Therapy Patient Assistance Program option 3 then ex MERCK & COMPANY, INC. ACT for EMEND Act Program - Zolinza Merck Hotline for Cancidas, Invanz & Primaxin

16 Merck Prescription Discount Program SUPPORT Program for Crixivan & Isentress The Merck Patient Assistance Program MERCK/SCHERING-PLOUGH Merck/Schering Plough Patient Assistance Program MILLENNIUM Velcade Reimbursement Assistance Program MISSION PHARMACAL Mission Pharmaceutical Patient Assistance Program MYLAN PHARMACEUTICALS Mylan Clozapine Prescription Access System NICHE PHARMACEUTICALS Niche Pharmaceuticals Patient Assistance Program NITROMED NitroMed Cares Uninsured Patient Program

17 NOVARTIS PHARMACEUTICALS CORPORATION Clozaril Patient Assistance Program EPASS Prescription and Reimbursement Hotline Extavia Patient Assistance Program Ilaris Patient Assistance Program Novartis Oncology Patient Assistance Program Novartis Patient Assistance Foundation Program Novartis Patient Assistance Program for Specialty Medicines Proleukin Reimbursement Service RabAvert Patient Assistance Program Reclast Patient Assistance Program Tobi Patient Assistance Program Visudyne Patient Assistance Program NOVEN THERAPEUTICS, LLC

18 JDS Patient Care Program NOVO NORDISK, INC. Novo Nordisk Diabetes Patient Assistance Program Novo Nordisk Hormone Therapy Patient Assistance Program PFIZER, INC. Connection to Care First Resource - Sutent First Resource Program Pfizer Bridge Program - Genotropin Pfizer Bridge Program - Genotropin (Pedi) Pfizer Bridge Program - Somavert Pfizer Maintain Program Pfizer RSVP Program PRIMUS PHARMACEUTICALS Primus Prescription Discounts

19 PROCTER & GAMBLE PHARMACEUTICALS, INC. Procter & Gamble Pharmaceuticals Patient Assistance Program PURDUE PHARMA Patient Assistance Program QUESTCOR PHARMACEUTICALS,INC. Acthar Gel Patient Assistance RARE DISEASE THERAPEUTICS,INC. Cystadane Patient Assistance Program Orfadin Patient Assistance Program RECKITT BENCKISER Suboxone Patient Assistance Program ROCHE DIAGNOSTIC CORPORATION Roche Diagnostic Corp. Patient Assistance Program ROCHE PHARMACEUTICALS Boniva Patient Assistance Program Roche Oncoline Patient Assistance Program

20 Roche Patient Assistance Program for HCV, HIV, and Transplants ROMARK LABORATORIES Romark Patient Assistance Program for Alinia SALIX PHARMACEUTICALS Salix Pharmaceuticals Patient Assistance Program SANOFI PASTEUR Sanofi Pasteur Patient Assistance Program SANOFI-AVENTIS Eligard Reimbursement Hotline & Patient Assistance Program Hyalgan Hotline and Patient Assistance Program Lovenox Reimbursement Services and Patient Assistance Program Multaq Patient Assistance Program and Reimbursement Hotline PACT+ Patient Assistance Program Rilutek Continuity Program Rilutek Patient Assistance Program or

21 Sanofi-Aventis Patient Assistance Program Sculptra Patient Access Program SCHERING CORPORATION Commitment to Care Program Schering-Plough Cares SCIELE PHARMA, INC. Patient Assistance Program SHIRE PHARMACEUTICALS Carbatrol Patient Assistance Program Fosrenol on Track Program Shire CARES - Lialda Shire CARES - Pentasa Vyvanse Patient Assistance Program SIGMA-TAU PHARMACEUTICALS,INC. Carnitor Drug Assistance Program

22 Matulane Patient Assistance Program SOLVAY PHARMACEUTICALS INC. Solvay Patient Assistance Program SPECTRUM PHAMACEUTICALS, INC. Zevalin Results STIEFEL LABORATORIES StiefelCare Program STRATIVA PHARMACEUTICALS Megace ES Patient Assistance Program TAKEDA PHARMACEUTICALS AMERICA Patient Assistance Program TEVA NEUROSCIENCE,INC. Copaxone Patient Assistance Program TEVA PHARMACEUTICALS Azilect Patient Assistance Program Clozapine Patient Assistance Program

23 Teva Assistance Program Tev-Tropin Patient Assistance Program THE MEDICINES COMPANY Hospital/Patient Assistance Program THREE RIVERS PHARMACEUTICALS Infergen Aspire Patient Assistance Program RibaCare Patient Assistance Program TRIAX PHARMACEUTICALS, LLC Patient Assistance Program UCB PHARMA, INC. UCB Patient Assistance Program UCYCLYD PHARMA,INC. Buphenyl Drug Assistance Program VALEANT PHARMACEUTICALS INTERNATIONAL Cesamet Patient Assistance Program Valeant Patient Assistance - Mysoline

24 Valeant Pharmaceuticals Patient Assistance Program VALIDUS PHARMACEUTICALS Equetro Shire Patient Assistance Program VIROPHARMA Cinryze Solutions Patient Support ViroPharma Patient Assistance Program WATSON PHARMACEUTICAL, INC. Trelstar Reimbursement Assistance Program Watson Iron Reimbursement Assistance Program WELLSPRING PHARMACEUTICAL CORPORATION Wellspring Patient Assistance Program WYETH PHARMACEUTICALS Patient Assistance for Relistor RapAssist - Rapamune Patient Assistance Program Reimbursement Support and Patient Assistance Program

25 Torisel Reimbursent Support and Patient Assistance Program Wyeth Factor Resource Program Wyeth Pharmaceutical Assistance Foundation XUBEX PHARMACEUTICAL Free 30 Day Medication Supply Xubex Pharmaceutical Services

Pharmaceutical Marketing Disclosures

Pharmaceutical Marketing Disclosures Pharmaceutical Marketing Disclosures July 1, 2007 June 30, 2008 Report of Vermont Attorney General William H. Sorrell April 2009 Prepared by staff of the Vermont Attorney General s Office: Wendy Morgan,

More information

As featured in. Orphan disease specialists find home with Big Pharma.

As featured in. Orphan disease specialists find home with Big Pharma. Orphan disease specialists find home with Big Pharma. By Maura Musciacco Senior Analyst January 2013 Tumbling over the patent cliff, many big pharma companies are being forced to find new strategies for

More information

Specialty Pharmacy Overview Brian Burke VP National Accounts 9/14/2012

Specialty Pharmacy Overview Brian Burke VP National Accounts 9/14/2012 Specialty Pharmacy Overview Brian Burke VP National Accounts 9/14/2012 Specialty Pharmacy Defined Specialty Pharmacy is the practice of dispensing complex therapies delivered by expert healthcare practitioners

More information

Director of Compliance

Director of Compliance TITLE COMPANY VP & Assoc General Counsel Lundbeck USA Director of Compliance Merck VP & CCO Sanofi Sr Corp Counsel Sr Mgr Global Training CCO VP Corp & Legal Affairs Par Pharmaceutical Dir Compliance Daiichi

More information

CHAPTER FOUR: CLINICAL TRIAL COST AND FUNDING... 30

CHAPTER FOUR: CLINICAL TRIAL COST AND FUNDING... 30 CHAPTER ONE: INTRODUCTION... 1 STUDY GOALS AND OBJECTIVES... 1 REASONS FOR DOING THE STUDY... 1 INTENDED AUDIENCE... 2 METHODOLOGY... 2 ANALYST CREDENTIALS... 2 SCOPE OF REPORT... 2 INFORMATION SOURCES...

More information

Trends in the pharmaceutical industry and potential impact on future innovation and access to medicines

Trends in the pharmaceutical industry and potential impact on future innovation and access to medicines Trends in the pharmaceutical industry and potential impact on future innovation and access to medicines The R&D Process: Long, Complex, and Costly Average cost of R&D is $1.2 Billion The Current Challenge

More information

Outcomes of Monitoring Committee Reviews. Medicines Australia Code of Conduct

Outcomes of Monitoring Committee Reviews. Medicines Australia Code of Conduct Outcomes of Monitoring Committee Reviews Medicines Australia Code of Conduct 1 Medicines Australia ABN 23 126 990 001 Level 1, 16 Napier Close Deakin ACT 2600 Phone: 02 6122 8500 Fax: 02 6122 8555 Web:

More information

ExL s Traceability and the Drug Quality and Security Act Conference

ExL s Traceability and the Drug Quality and Security Act Conference ExL s Traceability and the Drug Quality and Security Act Conference Sampling of Past Conference Participants Company IT Manager Senior IT Manager, Supply Chain (Track & Trace) Global Traceability Lead,

More information

6 th Proactive GCP Compliance Effective Risk- Based Approaches for Optimizing Clinical Quality

6 th Proactive GCP Compliance Effective Risk- Based Approaches for Optimizing Clinical Quality 6 th Proactive GCP Compliance Effective Risk- Based Approaches for Optimizing Clinical Quality March 24-25, 2015 Wyndham Philadelphia Historic District, Philadelphia, PA www.exlevents.com/gcp Sponsors

More information

ehealthinsight Series: Online Patient Recruitment Strategies

ehealthinsight Series: Online Patient Recruitment Strategies A Datamonitor report ehealthinsight Series: Online Patient Recruitment Strategies Published: May-08 Product Code: Providing you with: Overview of benefits and drawbacks of online Analysis of online patient

More information

The Hong Kong Association of The Pharmaceutical Industry

The Hong Kong Association of The Pharmaceutical Industry The Hong Kong Association of The Pharmaceutical Industry UNIT A, 20/F., TIMES MEDIA CENTRE, FAX: (852) 2865 6283 WEBSITE: www. hkapi.hk Position Paper on the Pharmacy and Poisons (Amendment) Bill 2014

More information

TABLE 2 RECOGNIZED AND POTENTIAL AUTOIMMUNE DISEASES AND THE SYSTEMS THEY EFFECT,

TABLE 2 RECOGNIZED AND POTENTIAL AUTOIMMUNE DISEASES AND THE SYSTEMS THEY EFFECT, CHAPTER ONE: INTRODUCTION... 1 REASONS FOR DOING THE STUDY... 1 STUDY GOALS AND OBJECTIVES... 1 SCOPE OF REPORT... 2 INTENDED AUDIENCE... 2 METHODOLOGIES AND INFORMATION SOURCES... 2 ANALYST CREDENTIALS...

More information

The Global Biotech Industry: Challenges & Opportunities Michael S. Rosen Rosen Bioscience Strategies

The Global Biotech Industry: Challenges & Opportunities Michael S. Rosen Rosen Bioscience Strategies The Global Biotech Industry: Challenges & Opportunities Michael S. Rosen Rosen Bioscience Strategies Greetings from Chicago! Beaches Yes! Pharma Beginnings! Bogota 1974 Selling Drugs in Colombia Global

More information

PPRS 2014 analysis of growth in spend of branded medicines. DH Leading the nation s health and care

PPRS 2014 analysis of growth in spend of branded medicines. DH Leading the nation s health and care PPRS 2014 analysis of growth in spend of branded medicines March 2015 Executive Summary IMS Health data shows growth in spend in 2014 (compared to 2013) of 8.2% on branded medicines. This is higher than

More information

Decision Matrix: Selecting a CRM Vendor in the Pharmaceutical Market (Competitor Focus)

Decision Matrix: Selecting a CRM Vendor in the Pharmaceutical Market (Competitor Focus) A Datamonitor report Decision Matrix: Selecting a CRM Vendor in the Pharmaceutical Market (Competitor Focus) Published: Oct 07 Product Code: DMTC2133 Providing you with: Identifies which technology vendors

More information

Rx-360 An International Pharmaceutical Supply Chain Consortium

Rx-360 An International Pharmaceutical Supply Chain Consortium Rx-360 An International Pharmaceutical Supply Chain Consortium Overview Rx-360 and the Audit Sharing Program September 2011 Rx-360 Members (Continuously updated list at www.rx-360.org) Manufacturers (24)

More information

Commercial Insight Osteoarthritis and Rheumatoid Arthritis

Commercial Insight Osteoarthritis and Rheumatoid Arthritis A Datamonitor In-Depth Analysis Commercial Insight Osteoarthritis and Rheumatoid Arthritis New Growth In A Mature Market Published: Jul-03 Product Code: DMHC1891 Why buy this analysis? Target current and

More information

CHEM-E4140 Selectivity 12. Pharma Business

CHEM-E4140 Selectivity 12. Pharma Business CHEM-E4140 Selectivity 12. Pharma Business Prof. Ari Koskinen Laboratory of Organic Chemistry C318 Pharma Business Total volume ca 1100 G$ (Shell 421G$; Walmart 486G$; Toyota 252 G$). Annually approx 25

More information

Med-Project LLC - Participating Drug Producers

Med-Project LLC - Participating Drug Producers Med-Project LLC - Participating Drug Producers Participating Drug Company 3M Critical and Chronical Care 3M Drug Delivery Systems 3M Infection Prevention 3M Oral Care AbbVie Inc. AbbVie Inc. ACADIA Pharmaceuticals

More information

Stakeholder Perspectives: Mild Cognitive Impairment and Dementia

Stakeholder Perspectives: Mild Cognitive Impairment and Dementia A Datamonitor In-Depth Analysis Stakeholder Perspectives: Mild Cognitive Impairment and Dementia Aricept in Race to Pioneer Unexplored Markets Published: Aug-03 Product Code: DMHC1924 Why buy this analysis?

More information

Issues Document: Patent Expirations (2013 2017)

Issues Document: Patent Expirations (2013 2017) EMERGINGTHERAPEUTICS Issues Document: Patent Expirations (2013 2017) Updated: 05/6/2013 Summary The patent wave roughly began in 2001 when the popular antidepressant drug Prozac (fluoxetine Lilly) became

More information

CO-PAY PROGRAMS FOR HIV and Hepatitis

CO-PAY PROGRAMS FOR HIV and Hepatitis CO-PAY PROGRAMS FOR HIV and Hepatitis CO-PAY PROGRAMS FOR HIV These programs offer assistance to people with private health insurance for the co-payments they have to make at the pharmacy for their HIV

More information

The Changing Direct-to- Consumer Advertising Landscape

The Changing Direct-to- Consumer Advertising Landscape A Datamonitor report The Changing Direct-to- Consumer Advertising Landscape How Direct-to-Consumer Advertising Affects Return on Investment Published: Dec-08 Product Code: Providing you with: An analysis

More information

The power of creativity www.originbranding.com. Pharmaceutical Branding 2012

The power of creativity www.originbranding.com. Pharmaceutical Branding 2012 The power of creativity www.originbranding.com Pharmaceutical Branding 2012 We are an independent, boutique agency passionately focused on developing pharmaceutical brands. For over 15 years we have delivered

More information

M&A und Allianzen in Life Science Aktuelle Entwicklungen und Trends

M&A und Allianzen in Life Science Aktuelle Entwicklungen und Trends M&A und Allianzen in Life Science Aktuelle Entwicklungen und Trends Symposium Life Science am Kapitalmarkt Frankfurt, 3. Juni 28 Global biotech industry Strong growth in most areas but Visible product

More information

KEEPING CLINICAL TRIALS IN AUSTRALIA

KEEPING CLINICAL TRIALS IN AUSTRALIA OCCASIONAL PAPER SERIES KEEPING CLINICAL TRIALS IN AUSTRALIA WHY ACTION IS NEEDED NOW OCCASIONAL PAPER SERIES > Medicines Australia is producing Occasional Papers to promote a contest of ideas, thought

More information

INCENTIVE COMPENSATION CONFERENCE

INCENTIVE COMPENSATION CONFERENCE Announcing the 2nd Annual ZS Associates INCENTIVE COMPENSATION CONFERENCE 08 September 23 24, 2008 Philadelphia, PA Incentive compensation greatly affects sales force motivation and morale. When designed

More information

Patient Assistance and Co-Pay Programs for HIV and Viral Hepatitis

Patient Assistance and Co-Pay Programs for HIV and Viral Hepatitis Patient Assistance and Co-Pay Programs for HIV and Viral Hepatitis Co-Pay Programs for HIV..... p.1 Co-Pay Programs for Hepatitis p.4 PAPs & Welvista for HIV..... p.2 PAPs for Viral Hepatitis...... p.5

More information

Pharmaceutical industry

Pharmaceutical industry 8 th March 2016 Pharmaceutical industry 2015 Global ranking strategy decisive The annual company reporting season is always an exciting period. It is an ideal time to update our industry statistics and

More information

It s In The Cards: Pharmaceutical Co-pay and Patient Assistance Programs. Jeff Berry Editor, Positively Aware

It s In The Cards: Pharmaceutical Co-pay and Patient Assistance Programs. Jeff Berry Editor, Positively Aware It s In The Cards: Pharmaceutical Co-pay and Patient Assistance Programs Jeff Berry Editor, Positively Aware PAPs, Co-Pays, and ADAPs, Oh My! Patient Assistance Programs (PAPs) provide free or low-cost

More information

Stakeholder Insight: Multiple Sclerosis Disease-modifying Efficacy and Side Effects Guide Treatment Choice

Stakeholder Insight: Multiple Sclerosis Disease-modifying Efficacy and Side Effects Guide Treatment Choice A Datamonitor report Stakeholder Insight: Multiple Sclerosis Disease-modifying Efficacy and Side Effects Guide Treatment Choice Published: Dec-06 Product Code: Providing you with: An overview of epidemiology,

More information

Ahighlight of the Pharma 50 ranking

Ahighlight of the Pharma 50 ranking www.pharmexec.com ELECTRONICALLY REPRINTED FROM JUNE 2014 Insight: The Accelerating Growth of Specialty Markets By Waseem Noor and Michael Kleinrock, IMS Photo: Thinkstock Ahighlight of the ranking over

More information

Building A Fully Integrated Biotech Company:

Building A Fully Integrated Biotech Company: BIOPHARMA BIOPHARMA STRATEGIES STRATEGIES Building A Fully Integrated Biotech Company: WHAT IT TAKES The transition from R&D to a fully integrated stage is a make-orbreak scenario for any biotech company.

More information

Shark Attack: Pharmaceutical Industry s Feeding Frenzy

Shark Attack: Pharmaceutical Industry s Feeding Frenzy Shark Attack: Pharmaceutical Industry s Feeding Frenzy Ver. 1.1 October 24, 2016 Prepared by the Institute for Health and Socio-Economic Policy The Institute for Health & Socio-Economic Policy (IHSP) is

More information

Commercial Perspectives: Multiple Sclerosis

Commercial Perspectives: Multiple Sclerosis A Datamonitor Report Commercial Perspectives: Multiple Sclerosis How to Find Opportunities in an Unremitting Market Published: Jun-04 Product Code: Providing you with: In-depth profiles of current market-leading

More information

Multiple Sclerosis Therapeutics to 2019 - Treatment Diversification, Increasing Efficacy, and Pipeline Innovation Combine to Drive Growth

Multiple Sclerosis Therapeutics to 2019 - Treatment Diversification, Increasing Efficacy, and Pipeline Innovation Combine to Drive Growth Brochure More information from http://www.researchandmarkets.com/reports/2640803/ Multiple Sclerosis Therapeutics to 2019 - Treatment Diversification, Increasing Efficacy, and Pipeline Innovation Combine

More information

PATIENT ASSISTANCE PROGRAMS ANTICOAGULANTS (sponsored by drug company)

PATIENT ASSISTANCE PROGRAMS ANTICOAGULANTS (sponsored by drug company) Program Phone #/Fax Dabigatran [Pradaxa ] Boehringer Ingelheim CARES Foundation Patient Assistance Program Boeringher Ingelheim CARES Foundation Those with Part D Eligible? Must have no prescription coverage

More information

Stakeholder Insight: Rheumatoid Arthritis Biologics battle up the treatment algorithm

Stakeholder Insight: Rheumatoid Arthritis Biologics battle up the treatment algorithm A Datamonitor report Stakeholder Insight: Rheumatoid Arthritis Biologics battle up the treatment algorithm Published: Sep-06 Product Code: Providing you with: Disease overview including epidemiology, physician

More information

Clinical trial research agreement Agreed schedule 4 or 7 clause amendments

Clinical trial research agreement Agreed schedule 4 or 7 clause amendments Clinical trial research agreement Agreed schedule 4 or 7 clause amendments Medicines Australia and Medical Technology Association of Australia templates The sponsors in the table have agreed clauses for

More information

Cancer Drugs Data, Analysis and Forecasts to 2023

Cancer Drugs Data, Analysis and Forecasts to 2023 Cancer Drugs Data, Analysis and Forecasts to 2023 Pharmaceutical, Commercial & Strategic Developments in the Global Cancer Drugs Market to 2023 GMRData.com 1. Executive Summary 1.1. Cancer Drugs Market

More information

Trends in Retail Prices of Specialty Prescription Drugs Widely Used by Older Americans, 2006 to 2013

Trends in Retail Prices of Specialty Prescription Drugs Widely Used by Older Americans, 2006 to 2013 November 2015 Research Report Trends in Retail Prices of Specialty Prescription Drugs Widely Used by Older Americans, 2006 to 2013 Stephen W. Schondelmeyer PRIME Institute University of Minnesota Leigh

More information

Pharma working capital performance highly variable

Pharma working capital performance highly variable April 2014 Pharma working capital performance highly variable 41 Billion in Excess Working Capital We last completed this survey in 2012. We expected that there would be a broad improvement across the

More information

CHAPTER SIX: SMALL MOLECULE MS DRUGS... 37

CHAPTER SIX: SMALL MOLECULE MS DRUGS... 37 CHAPTER ONE: INTRODUCTION... 1 STUDY GOALS AND OBJECTIVES... 1 REASONS FOR DOING THIS STUDY... 2 INTENDED AUDIENCE... 2 SCOPE OF REPORT... 3 METHODOLOGY... 3 INFORMATION SOURCES... 4 AUTHOR S CREDENTIALS...

More information

Annual Press Conference 2012. Business Year 2011

Annual Press Conference 2012. Business Year 2011 Business Year 2011 Highlights of the Business Year 2011 Andreas Barner Chairman of the Board of Managing Directors Corporate Board Division Pharma Research, Development and Medicine Value through Innovation

More information

PROGRAM PLAN FOR THE ONTARIO MEDICATIONS RETURN PROGRAM

PROGRAM PLAN FOR THE ONTARIO MEDICATIONS RETURN PROGRAM PROGRAM PLAN FOR THE ONTARIO MEDICATIONS RETURN PROGRAM April 2013 Executive Summary Ontario Regulation 298/12 "Collection of Pharmaceuticals and Sharps - Responsibility of Producers" came into force on

More information

Shifting paths of pharmaceutical innovation: Implications for the global pharmaceutical industry

Shifting paths of pharmaceutical innovation: Implications for the global pharmaceutical industry Shifting paths of pharmaceutical innovation: Implications for the global pharmaceutical industry Tariq Sadat PhD Candidate School of Economics, Finance and Marketing, RMIT University, Australia Roslyn

More information

Guide. Astellas Pharma US, Inc. XTANDI Access Services SM 2015 NCCN Virtual Reimbursement Resource Room. NCCN.org/reimbursement

Guide. Astellas Pharma US, Inc. XTANDI Access Services SM 2015 NCCN Virtual Reimbursement Resource Room. NCCN.org/reimbursement Astellas Pharma US, Inc. XTANDI Access Services SM 2015 NCCN Virtual Reimbursement Resource Room Guide The oncology reimbursement landscape continues to present ever-evolving challenges for clinicians

More information

全 球 多 发 性 硬 化 症 治 疗 市 场 研 究 报 告 Multiple Sclerosis Therapeutics - A Global Strategic Business Report

全 球 多 发 性 硬 化 症 治 疗 市 场 研 究 报 告 Multiple Sclerosis Therapeutics - A Global Strategic Business Report /wepdwukltuyot 全 球 多 发 性 硬 化 症 治 疗 市 场 研 究 报 告 Multiple Sclerosis Therapeutics - A Global Strategic Business Report 联 系 购 买 电 话 :010-82863480 公 司 名 称 : 佐 思 信 息 公 司 地 址 : 北 京 市 海 淀 区 苏 州 街 18 号 院 长 远 天

More information

Pharma working capital leaves room for improvement

Pharma working capital leaves room for improvement October 2012 Pharma working capital leaves room for improvement 50.7 Billion in Excess Working Capital Ten years ago it was not unusual to be asked why working capital mattered to a pharmaceutical company.

More information

Campbell Alliance. Press Kit Materials

Campbell Alliance. Press Kit Materials Campbell Alliance Press Kit Materials Raleigh, N.C. Parsippany, N.J. Woodland Hills, Calif. South San Francisco Chicago New York City TABLE OF CONTENTS Document Page # About Campbell Alliance 3 Company

More information

VAB REPORT: ITS TIME FOR A CHECK UP! UPDATE ON THE HEALTHCARE INDUSTRY

VAB REPORT: ITS TIME FOR A CHECK UP! UPDATE ON THE HEALTHCARE INDUSTRY VAB REPORT: ITS TIME FOR A CHECK UP! UPDATE ON THE HEALTHCARE INDUSTRY SUMMARY Healthcare Summary Personal health care expenditures projected to grow 26% in the next 4 years Hospital care sector comprises

More information

Key Findings. Use this report to... The Autoimmune Market Outlook to 2013

Key Findings. Use this report to... The Autoimmune Market Outlook to 2013 Key Findings The global autoimmune market generated sales of $31.9bn in, an increase of 14.4% over 2006 sales. The market is forecast to grow at a CAGR of 8.1% to reach a total value of $51.0bn in 2013.

More information

STAT Bulletin. Drug Therapy Guideline Updates. May 11, 2012 Volume: 18 Issue: 12

STAT Bulletin. Drug Therapy Guideline Updates. May 11, 2012 Volume: 18 Issue: 12 STAT Bulletin May 11, 2012 Volume: 18 Issue: 12 To: All primary care physicians and specialists Contracts Affected: All Lines of Business Drug Therapy Guideline Updates Why you re receiving this Stat What

More information

Pertuzumab in Trastuzumab- Treated, Advanced HER2-Positive Breast Cancer

Pertuzumab in Trastuzumab- Treated, Advanced HER2-Positive Breast Cancer Pertuzumab in Trastuzumab- Treated, Advanced HER2-Positive Breast Cancer For more visit ResearchToPractice.com/5MJC CME INFORMATION OVERVIEW OF ACTIVITY Each year, thousands of clinicians and basic scientists

More information

The Facts, Figures and Trends in U.S. Pharmaceutical Distribution Gayle C. Johnston, President, CuraScript SD Miguel Rodriguez, Senior Product

The Facts, Figures and Trends in U.S. Pharmaceutical Distribution Gayle C. Johnston, President, CuraScript SD Miguel Rodriguez, Senior Product The Facts, Figures and Trends in U.S. Pharmaceutical Distribution Gayle C. Johnston, President, CuraScript SD Miguel Rodriguez, Senior Product Manager, CuraScript SD 2015 Distribution Management Conference

More information

NCPA 2006 Exhibitors (as of 9/25/06) American Pharmacists Association www.aphanet.org Booth 907. /alert Marketing www.alertmarketing.

NCPA 2006 Exhibitors (as of 9/25/06) American Pharmacists Association www.aphanet.org Booth 907. /alert Marketing www.alertmarketing. NCPA 2006 Exhibitors (as of 9/25/06) /alert Marketing www.alertmarketing.com Booth 530 21st Century Healthcare www.21stcenturyvitamins.com Booth 147 A & D Medical Lifesource www.lifesourceonline.com Booth

More information

Insurance and Reimbursement Resources for MDS Patients

Insurance and Reimbursement Resources for MDS Patients Insurance and Reimbursement Resources for MDS Patients A Guide to Assistance Programs in the United States Third Edition the myelodysplastic syndromes foundation, inc. Published by The Myelodysplastic

More information

Global Non-Small Cell Lung Cancer Therapeutics Market 2015-2019

Global Non-Small Cell Lung Cancer Therapeutics Market 2015-2019 Brochure More information from http://www.researchandmarkets.com/reports/3453273/ Global Non-Small Cell Lung Cancer Therapeutics Market 2015-2019 Description: About non-small cell lung cancer therapeutics

More information

Patient Assistance Programs List by Drug Name - Updated 1/19/11

Patient Assistance Programs List by Drug Name - Updated 1/19/11 ALAMEDA COUNTY PUBLIC HEALTH DEPARTMENT Office of AIDS Administration 1000 Broadway, Suite 310 Oakland, CA 94607 Tel: (510) 268-7630 Fax: (510) 268-7631 Date: January 19, 2011 To: HIV / AIDS Community

More information

OFFICE OF ATTORNEY GENERAL LAWRENCE G. WASDEN AVERAGE WHOLESALE PRICE LITIGATION REPORT AUGUST 2013

OFFICE OF ATTORNEY GENERAL LAWRENCE G. WASDEN AVERAGE WHOLESALE PRICE LITIGATION REPORT AUGUST 2013 Introduction OFFICE OF ATTORNEY GENERAL LAWRENCE G. WASDEN AVERAGE WHOLESALE PRICE LITIGATION REPORT AUGUST 2013 In 2007, Attorney General Wasden filed lawsuits against 33 pharmaceutical companies for

More information

New Treatments. For Bipolar Disorder. Po W. Wang, MD Clinical Associate Professor Bipolar Disorders Clinic Stanford University School of Medicine

New Treatments. For Bipolar Disorder. Po W. Wang, MD Clinical Associate Professor Bipolar Disorders Clinic Stanford University School of Medicine New Treatments For Bipolar Disorder Po W. Wang, MD Clinical Associate Professor Bipolar Disorders Clinic Stanford University School of Medicine Abbott Laboratories AstraZeneca Bristol-Myers Squibb Corcept

More information

Pipeline Insight: Schizophrenia Asenapine; A future market leader?

Pipeline Insight: Schizophrenia Asenapine; A future market leader? A Datamonitor report Pipeline Insight: Schizophrenia Asenapine; A future market leader? Published: Jul-06 Product Code: DMHC2186 Providing you with: Detailed pipeline analysis for key products in development

More information

Stakeholder Insight: Insulin Use in Type 2 Diabetes

Stakeholder Insight: Insulin Use in Type 2 Diabetes A Datamonitor Report Stakeholder Insight: Insulin Use in Type 2 Diabetes From Last Resort to Early Intervention Published: May-04 Product Code: DMHC1989 Providing you with: Analysis of Datamonitor s Diabetes

More information

Reference Guide to Saving Money on Prescriptions

Reference Guide to Saving Money on Prescriptions Reference Guide to Saving Money on Prescriptions Revised: July 11, 2006 Prescription medications can be a heavy financial burden for individuals and families. Many people feel limited to receiving assistance

More information

The Future of Monoclonal Antibodies Therapeutics: Innovation in Antibody Engineering, Key Growth Strategies and Forecasts to 2011

The Future of Monoclonal Antibodies Therapeutics: Innovation in Antibody Engineering, Key Growth Strategies and Forecasts to 2011 Brochure More information from http://www.researchandmarkets.com/reports/344881/ The Future of Monoclonal Antibodies Therapeutics: Innovation in Antibody Engineering, Key Growth Strategies and Forecasts

More information

In the largest and perhaps the most ambitious collaborative

In the largest and perhaps the most ambitious collaborative FEATURES THE BIRTH OF TRANSCELERATE BIOPHARMA, INC. Revolution in Clinical Research Partnerships by Dalvir Gill and Garry Neil In the largest and perhaps the most ambitious collaborative effort ever initiated

More information

Specialty Pharmacy. Business Plan. July 8, 2013. 2013 RUSH University Medical Center

Specialty Pharmacy. Business Plan. July 8, 2013. 2013 RUSH University Medical Center Specialty Pharmacy Business Plan July 8, 2013 Specialty Pharmaceuticals What are they? Biotech/gene-based therapy Require special handling Newer products oral or self- administered One third have REMS

More information

REVISING SPECIALTY TIERS

REVISING SPECIALTY TIERS WHITE PAPER REVISING SPECIALTY TIERS PROTECTING MEDICARE PART D BENEFICIARIES FROM BURDENSOME COST SHIFTING Gary G., Michigan Gary thought he had his financial assistance grant set up to cover his out-of-pocket

More information

EFPIA Position Paper on REACH. Executive Summary. Position Paper. Draft Final. Author: EFPIA Date: October 2015 Version: Final

EFPIA Position Paper on REACH. Executive Summary. Position Paper. Draft Final. Author: EFPIA Date: October 2015 Version: Final Draft Final EFPIA Position Paper on REACH Author: EFPIA Date: October 2015 Version: Final Position Paper Executive Summary An increasing number of substances used in the pharmaceutical manufacturing process

More information

The United States False Claims Act Qui Tam Whistleblower Law

The United States False Claims Act Qui Tam Whistleblower Law The United States False Claims Act Qui Tam Whistleblower Law Getnick & Getnick LLP Counsellors At Law Rockefeller Center, 620 Fifth Avenue New York, NY 10020 Phone: (212) 376-5666 Fax: (212) 292 3942 www.getnicklaw.com

More information

Patient Assistance Programs

Patient Assistance Programs Patient Assistance Programs *Free Medication Programs *Discounted Medication *Discount Drug Cards *Reimbursement Programs *Glaucoma Medication Programs Since all drugs can not be listed here that patients

More information

The 2015 Avoca Report. Clinical Development Innovation. Sponsor and Provider Views on Innovation in Outsourced Clinical Development

The 2015 Avoca Report. Clinical Development Innovation. Sponsor and Provider Views on Innovation in Outsourced Clinical Development The 2015 Avoca Report Clinical Development Innovation Sponsor and Provider Views on Innovation in Outsourced Clinical Development Contents Section Slides Research Overview 3-5 Respondent Demographics 6-9

More information

Overview of Specialty Pharmacy. Kevin Colgan, MA, FASHP Corporate Director of Pharmacy Rush University Medical Center

Overview of Specialty Pharmacy. Kevin Colgan, MA, FASHP Corporate Director of Pharmacy Rush University Medical Center Overview of Specialty Pharmacy Kevin Colgan, MA, FASHP Corporate Director of Pharmacy Rush University Medical Center Conflicts of Interest Chair, UHC Specialty Pharmacy Committee Wife is a Specialty Pharmacist

More information

Specialty Drug Program RX Benefit Member Guide

Specialty Drug Program RX Benefit Member Guide Specialty Drug Program RX Benefit Member Guide bcbsm.com Enrollment Form for Walgreens Specialty Pharmacy, LLC. How to place your initial order with Walgreens Specialty Pharmacy: 1) Print and complete

More information

PATIENT ASSISTANCE PROGRAMS

PATIENT ASSISTANCE PROGRAMS PATIENT ASSISTANCE PROGRAMS Definitions SAP Class I Class II BC Cancer Agency Health Canada Special Access Program Reimbursed for active cancer or approved treatment or approved indication only Reimbursed

More information

Rx-360Upstream Supply Chain Security A Supplier Collaborative Approach to Mitigate Risk and Enhance Transparency

Rx-360Upstream Supply Chain Security A Supplier Collaborative Approach to Mitigate Risk and Enhance Transparency Rx-360Upstream Supply Chain Security A Supplier Collaborative Approach to Mitigate Risk and Enhance Transparency www.rx-360.org www.rx-360.org Presenter: Rob Welsh, VWR International, LLC VP Category Management

More information

EXPERT SPEAKER PANEL. Director, Portfolio Management Biologics Dr. Reddy s Laboratories. CEO Enrich. Executive Program Director ImmunoGen

EXPERT SPEAKER PANEL. Director, Portfolio Management Biologics Dr. Reddy s Laboratories. CEO Enrich. Executive Program Director ImmunoGen www.americanleaders.com 8 th Project and Portfolio Management for Pharma & Biotech Leveraging the Catalysts of Portfolio Success October 6-7, 2015 Hyatt Regency Boston Post-show report EXPERT SPEAKER PANEL

More information

Patient Assistance Programs

Patient Assistance Programs Patient Assistance Programs *Free Medication Programs *Discounted Medication *Discount Drug Cards *Reimbursement Programs *Glaucoma Medication Programs Since all drugs can not be listed here that patients

More information

FAHP 2015 Conference Attendee List -- Title and Organization. Business Organization Name

FAHP 2015 Conference Attendee List -- Title and Organization. Business Organization Name 2pointb 3M Health Information Systems, HEalth Plans AAAHC Accreditation Specialist, Health Plans AAAHC Managed Care Area Manager Abbvie of Sales Access2Care Manager, Client Relations Access2Care VP, Market

More information

Oracle Buys Phase Forward Expands Oracle s solutions for the life sciences and healthcare industries

Oracle Buys Phase Forward Expands Oracle s solutions for the life sciences and healthcare industries Oracle Buys Phase Forward Expands Oracle s solutions for the life sciences and healthcare industries April 16, 2010 Oracle is currently reviewing the existing Phase Forward product roadmap and will be

More information

Business Development & Licensing Journal For the Pharmaceutical Licensing Groups

Business Development & Licensing Journal For the Pharmaceutical Licensing Groups Issue 12 June 21 www.plg-uk.com Business Development & Licensing Journal For the Pharmaceutical Licensing Groups Follow-on biologics Co-marketing: a successful model Trends in dealmaking Finding new products

More information

Critical Path Institute

Critical Path Institute Critical Path Institute Accelerating drug development for Alzheimer s Disease through regulatory science Martha A. Brumfield, PhD President and CEO Accelerating the Path to a Healthier World 1 Critical

More information

Product Profiles: Multiple Sclerosis - Gilenya Raises Bar for New Market Entrants

Product Profiles: Multiple Sclerosis - Gilenya Raises Bar for New Market Entrants Brochure More information from http://www.researchandmarkets.com/reports/1841621/ Product Profiles: Multiple Sclerosis - Gilenya Raises Bar for New Market Entrants Description: Introduction Beginning with

More information

David Owen Licensing & IP business models. 27th of May, Paris

David Owen Licensing & IP business models. 27th of May, Paris David Owen Licensing & IP business models 27th of May, Paris LICENSING STRATEGY The key decision factors? Exclusive / non-exclusive? THESIS TTOs could and should make greater use of non-exclusive licensing

More information

Metastatic Breast Cancer - Pipeline Review, Q1 2011

Metastatic Breast Cancer - Pipeline Review, Q1 2011 Brochure More information from http://www.researchandmarkets.com/reports/1524592/ Metastatic Breast Cancer - Pipeline Review, Q1 2011 Description: Metastatic Breast Cancer - Pipeline Review, Q1 2011 Summary

More information

EU Clinical Trials Register

EU Clinical Trials Register EU Clinical Trials Register Sponsor Contact Information Abbott Laboratories Ltd Abbott House, Vanwall Business Park, Vanwall Road, Maidenhead, Berkshire SL6 4XE UK Telephone number +44 1628 644475 euclinicaltrials@abbott.com

More information

Complying with the FCPA - An Exploration of Ethical Issues Raised by Recent Cases: Lessons Learned from Recent Enforcement Actions

Complying with the FCPA - An Exploration of Ethical Issues Raised by Recent Cases: Lessons Learned from Recent Enforcement Actions Complying with the FCPA - An Exploration of Ethical Issues Raised by Recent Cases: Lessons Learned from Recent Enforcement Actions Philip S. Brewster Brewster Law Firm LLC July 29, 2014 Schering Charitable

More information

Avoca s Quality Metrics Consulting Service Offering

Avoca s Quality Metrics Consulting Service Offering Avoca s Quality Metrics Consulting Service Offering Avoca s Quality Metrics Consulting The Challenge Biopharmaceutical companies and CROs struggle in defining how best to utilize quality metrics to optimize

More information

N/A N/A N/A. Supporting statement of diagnosis from the N/A. physician and documented trial of 1 generic. formulary alternative

N/A N/A N/A. Supporting statement of diagnosis from the N/A. physician and documented trial of 1 generic. formulary alternative Actimmune Amlodipine Androderm Anticonvulsant Antidepressants Antineoplastics Antipsychotics Arcalyst Butalbital Colony Stimulating Factors ESRD Therapy Actimmune Norvasc Androderm Banzel Keppra Mysoline

More information

drugs in development CuraScript Specialty Pharmacy Management Guide & Trend Report

drugs in development CuraScript Specialty Pharmacy Management Guide & Trend Report CuraScript Specialty Pharmacy Management Guide & Trend Report Drugs in Development There are currently more than 324 drugs in development for nearly 150 disease states. These potential new medications

More information

December 17, 2014 HOW PHARMA MARKETERS FIND AND SELECT DIGITAL MARKETING AGENCIES

December 17, 2014 HOW PHARMA MARKETERS FIND AND SELECT DIGITAL MARKETING AGENCIES December 17, 2014 HOW PHARMA MARKETERS FIND AND SELECT DIGITAL MARKETING AGENCIES by Dennis van Rooij with Tim van Tongeren EXECUTIVE SUMMARY More than half of pharma marketers don t or can t leverage

More information

Trade Sales of Pharma and Biotechnology Companies 2005-2011

Trade Sales of Pharma and Biotechnology Companies 2005-2011 HBM Pharma/Biotech M&A Report Trade Sales of Pharma and Biotechnology Companies 05-11 The HBM Pharma/Biotech M&A Report covers all completed trade sales of North American (US and Canada) and European biotechnology,

More information

Family Practitioners, General Practitioners, Internists, Physician Assistants, Nurse Practitioners, and Nurses

Family Practitioners, General Practitioners, Internists, Physician Assistants, Nurse Practitioners, and Nurses 36 th Annual Family Practice Review Online Planned and produced in accordance with the ACCME essentials. RELEASE DATE: February 25, 2013 EXPIRATION DATE: February 25, 2015 Physicians $750 Non-Physicians

More information

Stakeholder Insight: Rheumatoid arthritis - Rising competition by line and severity

Stakeholder Insight: Rheumatoid arthritis - Rising competition by line and severity Brochure More information from http://www.researchandmarkets.com/reports/1383065/ Stakeholder Insight: Rheumatoid arthritis - Rising competition by line and severity Description: Introduction Disease-modifying

More information

Global Antibacterial Drugs Market

Global Antibacterial Drugs Market Brochure More information from http://www.researchandmarkets.com/reports/3498706/ Global Antibacterial Drugs Market 2015-2019 Description: About antibacterial drugs Antibacterial drugs are chemical compounds

More information

Sales Force Effectiveness in Pharmaceuticals

Sales Force Effectiveness in Pharmaceuticals Sales Force Effectiveness in Pharmaceuticals Targeted Sales Models such as Enhanced Key Account Management (KAM) and Closed-Loop Marketing (CLM) Strategies Drives Sales Force Efficiency GBI Research Report

More information

Patient Insights in Topical Therapy in Psoriasis. Dr. Kim Papp

Patient Insights in Topical Therapy in Psoriasis. Dr. Kim Papp Patient Insights in Topical Therapy in Psoriasis Dr. Kim Papp Speaker Disclosures Speaker, Consultant, Investigator Amgen *** Anacor *** AbbVie *** Active Biotech * Akesis * Allergan ** Astellas *** AstraZeneca

More information

HBM Pharma/Biotech M&A Report 2014

HBM Pharma/Biotech M&A Report 2014 January 1 HBM Pharma/Biotech M&A Report 14 including in-depth analysis of trade sales of US and European biopharma companies backed by venture- and private-equity investors Key Findings $1.4 billion wordwide

More information

An Overview of Risk and Disclosure in the Global Pharmaceutical and Life Sciences Industry

An Overview of Risk and Disclosure in the Global Pharmaceutical and Life Sciences Industry An Overview of Risk and Disclosure in the Global Pharmaceutical and Life Sciences Industry April 2012 kpmg.com KPMG INTERNATIONAL Contents Executive summary 2 Reported risk factors 4 Financial statement

More information

Toulouse University, Hôpital Larrey, Toulouse, France

Toulouse University, Hôpital Larrey, Toulouse, France 2177 Long-term Safety and Tolerability of Apremilast in Patients With Psoriasis: Analysis of Two Phase 3, Randomized, Controlled Trials (ESTEEM 1 and 2) Kristian Reich, MD 1 ; Kim Papp, MD 2 ; Kenneth

More information